Former FDA deputy commissioner Dr. Scott Gottlieb is the rumored choice to head the agency, with the full nomination expected by the end of the day. Like most of the Trump Administration’s other high-office picks, Gottlieb is known for his anti-regulatory stance and is in favor of speeding up the drug-approval process, especially for older generics. Considered more mainstream than earlier choices...
